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ABSTRACT
Introduction Docosahexaenoic acid (DHA) is an omega-3 
(n-3) fatty acid that accumulates into neural tissue 
during the last trimester of pregnancy, as the fetal brain 
is undergoing a growth spurt. Infants born <29 weeks’ 
gestation are deprived the normal in utero supply of DHA 
during this period of rapid brain development. Insufficient 
dietary DHA postnatally may contribute to the cognitive 
impairments common among this population. This follow- 
up of the N-3 fatty acids for improvement in respiratory 
outcomes (N3RO) randomised controlled trial aims to 
determine if enteral DHA supplementation in infants 
born <29 weeks’ gestation during the first months of 
life improves cognitive development at 5 years of age 
corrected for prematurity.
Methods and analysis N3RO was a randomised 
controlled trial of enteral DHA supplementation (60 mg/kg/
day) or a control emulsion (without DHA) in 1273 infants 
born <29 weeks’ gestation to determine the effect on 
bronchopulmonary dysplasia (BPD). We showed that DHA 
supplementation did not reduce the risk of BPD and may 
have increased the risk.
In this follow- up at 5 years’ corrected age, a predefined 
subset (n=655) of children from five Australian sites 
will be invited to attend a cognitive assessment with a 
psychologist. Children will be administered the Wechsler 
Preschool and Primary Scale of Intelligence (fourth edition) 
and a measure of inhibitory control (fruit stroop), while 
height, weight and head circumference will be measured.
The primary outcome is full- scale IQ. To ensure 90% 
power, a minimum of 592 children are needed to detect a 
four- point difference in IQ between the groups.
Research personnel and families remain blinded to group 
assignment.
Ethics and dissemination The Women’s and Children 
Health Network Human Research Ethics Committee 
reviewed and approved the study (HREC/17/WCHN/187). 
Caregivers will give informed consent prior to taking 
part in this follow- up study. Findings of this study will be 
disseminated through peer- reviewed publications and 
conference presentations.
Trial registration number ACTRN12612000503820.
INTRODUCTION
Medical and technological advances in the 
care of infants born preterm have increased 
their survival rates. However, there is a high 
risk of long- term health complications and 
neurological deficits with preterm birth,1–4 
Strengths and limitations of this study
 ► This will be the first adequately powered randomised 
controlled trial to assess cognitive development fol-
lowing docosahexaenoic acid (DHA) supplementa-
tion in preterm infants born <29 weeks’ gestation.
 ► This follow- up of the N-3 fatty acids for improve-
ment in respiratory outcomes (N3RO) trial will pro-
vide sound evidence for the effect of enteral DHA 
supplementation on the cognitive development of 
infants born <29 weeks’ gestation.
 ► Lost to follow- up 5 years after enrolment into the 
trial may contribute to risk of bias.
 ► Partial unblinding of study group allocation permit-
ted under the primary protocol may contribute to 
risk of bias.
 ► Although bronchopulmonary dysplasia was the 
primary outcome of the original N3RO trial, child-
hood respiratory functioning is not assessed in this 
follow- up
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including higher risks of cognitive deficits5 6 and 
behavioural problems3 6–11 compared with term- born 
counterparts. The risk and severity of poor outcome 
increases as gestational age decreases.4 8 12 13
Nutrition is thought to be one modifiable influence 
on neurodevelopment in preterm infants, in particular 
the omega-3 (n-3) long- chain polyunsaturated fatty acid 
(LCPUFA), docosahexaenoic acid (DHA). During the last 
trimester of pregnancy, the fetus is estimated to acquire 
~70 mg/day of n-3 LCPUFA, largely as DHA.14 Infants 
born preterm are deprived of the placental transfer of 
DHA and hence have lower neural tissue levels of DHA 
compared with infants born at term.15 It has been hypoth-
esised that providing infants born preterm with DHA may 
enhance normal neurodevelopment and the most recent 
recommendations are that the preterm infant needs 
approximately 60 mg/kg/day DHA (about 1% of total 
dietary fatty acids) to approximate the fetal accumulation 
rate.16
Several randomised controlled trials (RCTs) have 
attempted to evaluate this hypothesis, with mixed 
results.17 18 Two RCTs compared the standard dose of 
DHA in breastmilk and preterm infant formula (20 mg/
kg/day) to the estimated in utero accretion rate (60 mg/
kg/day).19 20 In one trial, the DHA group showed greater 
problem solving skills at 6 months20 and improved 
sustained attention at 20 months,21 although attrition was 
high. In the larger trial, assessment at 18 months revealed 
no difference in overall mean cognitive scores but fewer 
infants had developmental delay in the DHA group.19 
No overall differences in IQ were detected in follow- up 
of these trials at seven22 or 8 years of age.23 Interestingly, 
both trials suggested a benefit of extra DHA in infants 
born at the earliest gestations (<29 weeks or <1250 g) 
who are most vulnerable to experiencing neurodevel-
opmental deficit.19 20 While this is promising, both trials 
were significantly underpowered (with only 200 children 
in one trial19 and under 70 in the other20) to detect an 
effect in this subgroup.
It is clear that current neonatal feeding practices are 
unable to replace the placental transfer of DHA16 and 
despite decades of research, we still do not know whether 
meeting the estimated requirement of DHA during the 
neonatal period improves cognitive outcomes in the most 
vulnerable subpopulation of preterm infants.17 19 20 22 23
The N-3 fatty acids for improvement in respiratory 
outcomes (N3RO) RCT was designed to determine the 
effect of an enteral DHA emulsion (providing 60 mg/kg/
day) on the incidence of bronchopulmonary dysplasia 
(BPD).24 The DHA intervention did not lower the inci-
dence of BPD in infants born <29 weeks’ gestation and 
may have resulted in a greater risk of BPD.24 However, the 
N3RO trial offers an ideal opportunity to resolve whether 
DHA supplementation is beneficial for the cognitive 
development of these most vulnerable preterm infants.
The N3RO trial infants are now reaching 5 years of age. 
Cognition develops rapidly across early childhood25 and 
by 5 years most cognitive domains can be reliably assessed 
using standardised psychometric tests.26 IQ tests are 
considered a robust method of estimating an individual’s 
overall cognitive ability. Executive function is an umbrella 
term referring to those skills essential for undertaking 
goal- oriented behaviours and includes inhibitory control 
which has been reported to be an area of concern for 
children born preterm.6
By assessing the cognition of the N3RO infants as they 
turn 5 years of age, we can determine whether providing 
infants born <29 weeks’ gestation with DHA emulsion 
improves cognitive development. We hypothesise that 
providing the estimated in utero provisions of DHA to 
infants born <29 weeks’ gestation will result in higher 
cognitive scores at 5 years’ corrected age compared with 
infants who received the control intervention.
METHODS AND ANALYSIS
This protocol details the methods for a follow- up at 5 years 
of age of infants enrolled in the N3RO trial. Detailed 
methods of the N3RO trial have been published previ-
ously24 and are summarised here.
The N3RO trial
A total of 1273 infants born <29 weeks’ gestation were 
enrolled into the N3RO trial within 3 days of their first 
enteral feed. Infants were recruited between June 2012 
and September 2015 from 13 centres in Australia, New 
Zealand and Singapore.24 Infants were excluded if they 
had a major congenital or chromosomal abnormality, 
were participating in another fatty acid intervention 
trial, were receiving intravenous lipids containing fish 
oil, or if a breastfeeding mother was taking greater than 
250 mg/day DHA through supplements.24 Infants were 
randomised to the intervention or control group through 
a secure web- based computer- generated schedule strati-
fied for the 13 centres, sex and gestational age at birth 
<27 weeks’ or 27 to <29 weeks’ gestation. Infants from 
multiple births were randomised individually. A statisti-
cian not otherwise involved in the N3RO trial generated 
the randomisation schedule.
The N3RO trial intervention
Infants were randomised to receive a DHA emulsion 
that provided 60 mg of DHA per kg of body weight per 
day (intervention group, n=631), or a control emulsion 
without DHA (control group, n=642).24 Infants received 
the study intervention from enrolment to 36 weeks’ post-
menstrual age or discharge home, whichever occurred 
first. The emulsion was administered three times per day, 
immediately before an enteral feed through a nasogastric 
or orogastric tube for the duration of the intervention 
period. The DHA and control emulsions were isocaloric 
and identical in viscosity, colour and packaging and fami-
lies, clinical staff and study personnel were blinded to 
group allocation.24
Five-year follow-up study procedure
This is a follow- up of a predefined subsample of the N3RO 
trial infants from five of the Australian recruiting centres. 
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No additional interventions will be administered. Eligible 
N3RO infants will be invited to attend an appointment 
with a psychologist when they are 5 years’ corrected age to 
measure child abilities on selected cognitive domains; age 
is corrected for prematurity to avoid a known bias in cogni-
tive test scores.27 Appointments will take between 45 min 
to 1.5 hours, depending on the child’s abilities and speed 
while working through the IQ test tasks, and assessments 
will be conducted by personnel blinded to group alloca-
tion. Assessments for this follow- up study commenced 29 
August 2018 and are expected to be completed on the 31 
December 2020.
Families of eligible children will be emailed a letter of 
invitation 2 months before their child reaches 5 years’ 
corrected age, followed by a telephone call to answer any 
questions and book appointments with families that wish 
to participate. Where necessary, families will be offered 
appointments at the family’s home or at a location close 
to their home such as a school or community centre.
Participants and sample selection
Children who participated in the N3RO trial and were 
recruited from the five largest recruiting centres, John 
Hunter Hospital (New South Wales), King Edward Memo-
rial Hospital (Western Australia), Mercy Hospital for 
Women (Victoria), Royal Women’s Hospital (Victoria), 
and the Women’s and Children’s Hospital (South 
Australia) in Australia will be invited to participate in 
this follow- up study. Children will not be invited if they 
have previously been withdrawn from the N3RO trial or 
have died. Of the n=702 children enrolled between the 
five centres, n=655 will be eligible to be approached for 




The primary outcome is full- scale IQ, as assessed by the 
Wechsler Preschool and Primary Scale of Intelligence- 
Fourth Edition, Australian and New Zealand (WPPSI- IV). 
The WPPSI- IV is a battery of subtests that provides an 
assessment of general cognitive ability for preschoolers 
and young children (2:6–7:7 years). The WPPSI- IV has 
strong internal consistency and test–retest stability and 
sound psychometric properties.28 The average reliability 
coefficient for the full- scale IQ is 0.95.28
Secondary outcomes
Wechsler Preschool and Primary Scale of Intelligence-Fourth 
Edition, Australian and New Zealand
Other outcomes from the WPPSI- IV will be included as 
secondary outcomes. These include Verbal Compre-
hension, Fluid Reasoning, Working Memory and the 
Processing Speed, General Ability and Cognitive Profi-
ciency Primary Index Scales.
The WPPSI- IV has Australian/New Zealand norms that 
are age standardised with a mean of 100 and SD 15. Intel-
lectual impairment will be defined as full- scale IQ <85 (ie, 
≤1 SD), and moderate- to- severe intellectual impairment 
as full- scale IQ<70 (ie, ≤2 SD). Any impairment on any of 
the WPPSI- IV Primary Index Scales will be defined as an 
Index Scale score <85 (ie, ≤1 SD).
Fruit Stroop
The fruit stroop was administered to assess two executive 
functions, inhibition and mental flexibility.29 The child 
is required to identify a the correct, natural colour of 
a series of fruits and vegetables in four 45 s trials under 
a series of conditions that increase in complexity. The 
outcome is an interference score calculated as the differ-
ence between the number of correct responses on the 
final (inhibition) trial, and predicted scores on the first 
and third trials, where lower or negative values indicate 
more interference.
Growth
Anthropometrics including child height, weight and 
head circumference will be measured at the appointment 
as measures of the nutritional well- being of the children. 
Measurements will be converted to Z (SD) scores appro-
priate for corrected age and sex.30
Background information and characteristics
At enrolment into the N3RO trial a range of sociodemo-
graphic data were collected through interview with the 
caregiver (including parental age, education and employ-
ment). As part of the N3RO trial infant medical records 
were used to determine a range of baseline and outcome 
clinical characteristics up to 40 weeks’ postmenstrual 
age or first discharge home, whichever occurred first, 
including, for example, gestational age, birth weight, sex 
and instances of intraventricular haemorrhage.
Sample size calculation
A sample size of 296 children per group (total 592) will 
provide 90% power (two- tailed alpha 0.05) to detect a 
4- point (0.27 SD) mean difference in the primary outcome 
of full- scale IQ between groups. The power calculation 
assumes a design effect due to the inclusion of multiple 
births of one, since children from a multiple birth were 
randomised individually in N3RO.31 Should enrolment 
be lower than planned, the study will have 80% power to 
detect a 4- point difference between groups provided at 
least 222 children per group (total 444) provide follow- up 
data.
Data management and analysis plan
All participants were assigned a study identification 
number at enrolment into the N3RO trial. Throughout 
the follow- up and analyses, the identification number 
will be used to identify data. Data will be entered into a 
Research Electronic Data Capture (REDCap) database, 
which uses a MySQL database via a secure web interface 
with data checks used during data entry to ensure data 
quality. REDCap includes a complete suite of features to 
support the Health Insurance Portability and Account-
ability Act of 1996 compliance, including a full audit trail, 
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user- based privileges and integration with the institu-
tional Lightweight Directory Access Protocol server.
All analyses will be conducted according to a prespeci-
fied statistical analysis plan. Analyses will not commence 
until the N3RO trial Steering Committee has approved 
the statistical analysis plan. Intervention groups will be 
dummy coded to allow analyses to be performed blinded 
to treatment group.
Outcomes of intervention and control group children 
will be compared using generalised linear models, with 
generalised estimated equations used to account for 
clustering due to multiple births within the same family. 
Continuous and binary outcomes will be analysed using 
linear and log binomial models, respectively, with adjust-
ment for variables used to stratify the randomisation: 
sex, centre enrolled and gestational age (<27 completed 
weeks’ or 27 to <29 weeks’ at birth). Preplanned subgroup 
analyses will examine the effects of DHA separately for 
girls or boys (all outcomes), and for infants born at <27 
weeks’ gestation or 27 to <29 weeks’ gestation (primary 
outcome only). No adjustment will be made for multiple 
preplanned comparisons, as the single overall comparison 
of Full- Scale IQ between groups is of primary interest.
Missing outcome data will be addressed using multiple 
imputation, with imputation performed separately by 
treatment group using fully conditional specification.32 
Imputed datasets will include all surviving children from 
the five included centres. Children who are missing scores 
on psychological assessments because they were unable to 
complete the assessment for cognitive or physical reasons 
(such as blindness or cerebral palsy) will be reviewed by 
a psychologist to determine whether assigning the lowest 
possible score is appropriate.
Ethics and dissemination
This follow- up study will be carried out in accordance with 
the Australian National Statement on Ethical Conduct in 
Research Involving Humans, which builds on the ethical 
codes of the Declaration of Helsinki and the principles of 
International Conference on Harmonisation Good Clin-
ical Practice (as adopted in Australia). All procedures 
and study materials have been reviewed and approved 
by the Women’s and Children’s Health Network Human 
Research Ethics Committee (HREC/17/WCHN/187), as 
well as the research governance officers at each site.
Caregivers will be provided with a detailed information 
sheet about the study and will provide informed consent 
for their child’s involvement in the study. Caregivers will 
be free to renegotiate consent for each procedure in the 
follow- up study and are able to decline any part of the 
follow- up. Caregivers will be free to withdraw their chil-
dren from the study at any time.
The results of this follow- up study will be presented at 
academic conferences and published in peer- reviewed 
journals. Participating families will receive a lay report of 
the study findings. No participants will be identified in 
the dissemination of study results and data collected will 
be treated with confidence.
Access to data
Individual participant data, including data dictionaries, 
may be shared after deidentification on reasonable 
request. Proposals to access the data must be scientifi-
cally and methodologically sound and must be reviewed 
and approved by the N3RO trial steering committee and 
the Women’s and Children’s Human Research Ethics 
Committee. To gain access, data requestors will need 
to sign a data access agreement. Proposals should be 
directed to Jacqueline Gould through email ( Jacqueline. 
gould@ sahmri. com).
Patient and public involvement
Neither patients nor the public were directly involved in 
the development of the research question or design of 
this follow- up study. However, our primary outcome of IQ 
is based on reported concerns over long- term develop-
mental concerns from parents of preterm infants.33
A community board, comprising parents (including 
parents of a child born preterm) as well as clinicians and 
researchers specialising in paediatrics, will be consulted 
for the dissemination of the study findings to partici-
pants, including reviewing the study results and format 
of dissemination.
DISCUSSION
This protocol details a follow- up of an RCT of a DHA 
enteral emulsion (60 mg/kg/day) compared with a 
control emulsion (no DHA), for preterm infants born 
<29 weeks’ gestation in the first months of life, to eval-
uate the effect on child cognitive ability at 5 years of 
age. Unlike previous DHA RCTs in preterm popula-
tions,17 18 our follow- up has the benefits of a population 
likely to be insufficient in DHA,34 and a robust method of 
intervention.24
We previously conducted a follow- up of a small 
subgroup of the N3RO trial infants when they were aged 
18 months’ corrected age. Children underwent an exper-
imental assessment of visual attention (considered to be 
a basic, early emergence of higher order cognitive skills 
known as the executive functions).35 Where available, 
Bayley Scales of Infant and Toddler Development- third 
edition Cognition, Motor and Language assessment 
results were collected from hospital records.35 No statis-
tically significant differences were found for attention, 
cognition, motor or language abilities.36 However, assess-
ments of cognition during infancy are considered poor 
predictors of later performance,37–41 and the sample was 
small and underpowered to detect a clinically important 
effect on cognition.35
Our sample size calculation for the primary outcome 
requires a 90% follow- up rate of the N3RO trial chil-
dren, 5 years after enrolment. More than 10% lost to 
follow- up may introduce attrition bias. After comple-
tion of the N3RO trial primary outcome analyses, fami-
lies had the opportunity to request knowledge of their 
group allocation. Although few families requested this, 
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knowledge of their randomisation group prior to the 
5 year follow- up assessment may introduce additional 
bias to the results.
For this follow- up, we have carefully selected a robust 
assessment of general cognitive abilities, including exec-
utive functioning (both of which domains are likely to be 
adversely affected by very preterm birth)42–44 to be admin-
istered at an age when cognitive domains can be reli-
ably assessed,26 45 as well as ensuring a large, adequately 
powered sample. As per the recommendations of a 
consortium of parents and clinicians caring for high- risk 
preterm infants, we are assessing general cognitive ability 
using a Wechsler scale, which is considered the gold stan-
dard, and have included an assessment of growth.46 Assess-
ments of respiratory functioning are unreliable in early 
childhood and hence were not included in this follow- up. 
It is important that the long- term respiratory effects of 
DHA supplementation in infants born <29 weeks’ gesta-
tion is addressed when the N3RO trial children reach an 
appropriate age.
This project has global significance, with over one 
million infants born <29 weeks’ gestation each year, 
and the number rising.47 The potential benefit of DHA 
on cognitive performance has never been adequately 
demonstrated in this population. However, because of 
the N3RO primary results it is extremely unlikely that 
such a trial will be repeated. The N3RO cohort may repre-
sent the only children in which the longer- term cognitive 
and behavioural effects of DHA supplementation in these 
infants can be assessed.
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